Literature DB >> 30614390

Recessive congenital methemoglobinemia type II: Hypoplastic basal ganglia in two siblings with a novel mutation of the cytochrome b5 reductase gene.

Manal Nicolas-Jilwan1.   

Abstract

Recessive congenital methemoglobinemia type II is a very rare autosomal recessive hematologic disorder due to NADH-cytochrome b5 reductase deficiency, usually caused by full-stop mutations or deletions. This disease classically presents with mild neonatal cyanosis, early onset severe progressive developmental delay, movement disorders, and progressive microcephaly. We report two siblings with recessive congenital methemoglobinemia type II whose evaluation revealed a novel p.Arg92Trp missense mutation of the CYB5R3 gene and a peculiar imaging finding of basal ganglia hypoplasia. Brain magnetic resonance imaging was performed at age 10 months in the older sibling and at age three months in the younger sibling. It revealed similar findings of bilateral small size of the lentiform and caudate nuclei and reduced frontotemporal brain volume. Our patient cases highlight that basal ganglia hypoplasia is an interesting clue to the very rare and frequently unsuspected diagnosis of recessive congenital methemoglobinemia type II, that may explain the associated movement disorders. The novel missense mutation is one of very few identified missense mutations known to cause severe type II recessive congenital methemoglobinemia.

Entities:  

Keywords:  CYB5R3 gene; Methemoglobinemia; basal ganglia hypoplasia; cyanosis; cytochrome b5 reductase

Mesh:

Substances:

Year:  2019        PMID: 30614390      PMCID: PMC6410459          DOI: 10.1177/1971400918822153

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  14 in total

1.  Serine-proline replacement at residue 127 of NADH-cytochrome b5 reductase causes hereditary methemoglobinemia, generalized type.

Authors:  Y Kobayashi; Y Fukumaki; T Yubisui; J Inoue; Y Sakaki
Journal:  Blood       Date:  1990-04-01       Impact factor: 22.113

2.  Seven new mutations in the nicotinamide adenine dinucleotide reduced-cytochrome b(5) reductase gene leading to methemoglobinemia type I.

Authors:  J Dekker; M H Eppink; R van Zwieten; T de Rijk; A F Remacha; L K Law; A M Li; K L Cheung; W J van Berkel; D Roos
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

Review 3.  Normal myelination: a practical pictorial review.

Authors:  Helen M Branson
Journal:  Neuroimaging Clin N Am       Date:  2013-02-15       Impact factor: 2.264

4.  A case of methemoglobinemia type II due to NADH-cytochrome b5 reductase deficiency: determination of the molecular basis.

Authors:  C M Aalfs; G B Salieb-Beugelaar; R J Wanders; M M Mannens; F A Wijburg
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

5.  Heterogeneity of the molecular biology of methemoglobinemia: a study of eight consecutive patients.

Authors:  Jey Maran; Yongli Guan; Ching-Nan Ou; Josef T Prchal
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

6.  Cerebellar atrophy in a child with hereditary methemoglobinemia type II.

Authors:  Carlo Fusco; Giuliana Soncini; Daniele Frattini; Elvio Della Giustina; Cristina Vercellati; Elisa Fermo; Paola Bianchi
Journal:  Brain Dev       Date:  2010-07-22       Impact factor: 1.961

Review 7.  Recessive hereditary methaemoglobinaemia, type II: delineation of the clinical spectrum.

Authors:  C Ewenczyk; A Leroux; A Roubergue; V Laugel; A Afenjar; J M Saudubray; P Beauvais; T Billette de Villemeur; M Vidailhet; E Roze
Journal:  Brain       Date:  2008-01-17       Impact factor: 13.501

8.  Congenital Methemoglobinemia Type II-Clinical Improvement with Short-Term Methylene Blue Treatment.

Authors:  Monica S Cooper; Melinda Randall; Margaret Rowell; Margaret Charlton; Anthea Greenway; Chris Barnes
Journal:  Pediatr Blood Cancer       Date:  2015-11-17       Impact factor: 3.167

Review 9.  (1)H MR spectroscopy in pediatrics.

Authors:  Monika Dezortova; Milan Hajek
Journal:  Eur J Radiol       Date:  2008-04-21       Impact factor: 3.528

10.  Severe neurological impairment in hereditary methaemoglobinaemia type 2.

Authors:  Sandra P Toelle; Eugen Boltshauser; Ekkehard Mössner; Karin Zurbriggen; Stefan Eber
Journal:  Eur J Pediatr       Date:  2004-02-18       Impact factor: 3.183

View more
  1 in total

Review 1.  Recommendations for diagnosis and treatment of methemoglobinemia.

Authors:  Achille Iolascon; Paola Bianchi; Immacolata Andolfo; Roberta Russo; Wilma Barcellini; Elisa Fermo; Gergely Toldi; Stefano Ghirardello; Davis Rees; Richard Van Wijk; Antonis Kattamis; Patrick G Gallagher; Noemi Roy; Ali Taher; Razan Mohty; Andreas Kulozik; Lucia De Franceschi; Antonella Gambale; Mariane De Montalembert; Gian Luca Forni; Cornelis L Harteveld; Josef Prchal
Journal:  Am J Hematol       Date:  2021-09-23       Impact factor: 13.265

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.